Overview: The results from the Phase 3 CheckMate-8HW trial have just been released, demonstrating significant improvements in outcomes for patients with metastatic colorectal cancer (mCRC) exhibiting high-level microsatellite instability or deficient mismatch repair (MSI-H/dMMR). This study marks the first direct comparison between dual and single-agent immunotherapy in this patient population. Key Findings: Study Details: Implications … Continue reading Nivolumab + Ipilimumab Shows Improved Outcomes in MSI-H/dMMR mCRC CheckMate-8HW Trial